Skip to content
  • (312) 598-2610
  • info@ipfdalaw.com
  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
Untitled design (7)
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
  • About
    • Detailed Description
    • Our Team
    • Fee Structures
  • Services
    • Patent Litigation
    • Commercial Litigation
    • False Advertising & Unfair Competition
    • Generic Drugs
    • Branded Drugs and 505(b)(2)
    • Medical Devices
    • FDA/Exclusivity/GMP
    • Contracts & Licensing
    • Government Investigations
  • News
  • Videos
  • Recent Cases
  • Contact Us
中文

Day: September 7, 2023

How a Generic Drug Can Become A Branded Drug: A Case Study – Is Par’s Varenicline Trying?

Typically, brand and generic drugs stay nicely in their own lanes. The consuming public generally knows when the drug taken is branded or generic. But are there times when a generic drug may become a branded drug, whether unintentionally or intentionally? And when we say a branded drug in this context, we do not mean […]

Patents
Hatch-Waxman Litigation
Trade Secrets
Antitrust/Unfair Competition
FDA Counseling
Branded/Generic/ 505(b)(2)
Life Cycles
Contracts Licensing
Freedom to Operate

Quick Contact

Address

  • 109 Symonds Drive, #174, Hinsdale, IL 60522-0174
  • (312) 598-2610
  • info@ipfdalaw.com

Ⓒ 2021 - IPFDA law All Rights Are Reserved